Everest Medicines Limited (Everest Med) filed its monthly return for June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a minor expansion of its share base driven by staff option exercises.

Share Capital Structure • Authorised capital remained unchanged at 500.00 million ordinary shares with a par value of USD 0.0001, equivalent to USD 50,000. • Issued shares rose to 353.83 million, up by 6,900 shares (0.002 percent) from the prior month. No treasury shares are held. • The public float continues to meet the Main Board’s minimum 25 percent requirement.

Equity Incentive Activity • Post-IPO Share Option Scheme: 6,900 options were exercised, generating HKD 0.12 million in proceeds, while 119,982 options lapsed. Outstanding options under this scheme total 20.81 million. • Pre-IPO Employee Share Option Plan: 158,573 options remain outstanding; no exercises occurred. • 2026 Share Scheme: Approved on 24 February 2026 with a capacity of 35.36 million shares; no grants have been made.

Share Awards and RSUs • Shares that may be issued upon vesting total 2.71 million under the Pre-IPO plan and 0.96 million under the Post-IPO share award scheme. • During June, 28,500 RSUs vested, while 28,829 RSUs (Pre-IPO plan) and 38,664 awards (Post-IPO scheme) were cancelled. • No awards have yet been granted under the new 2026 Share Scheme.

Other Securities • The company reported no warrants, convertibles, or other agreements affecting share capital during the month.

With only 6,900 new shares issued, Everest Med’s share dilution in June was negligible, and the company maintained full compliance with Hong Kong listing rules regarding public float.